Search Result

Results for "

PARP+Inhibitors

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (6) Autophagy (7) Bacterial (2) Bcl-2 Family (1) Caspase (1) CDK (3) Deubiquitinase (1) DNA/RNA Synthesis (5) Drug Metabolite (1) Endogenous Metabolite (3) ERK (1) IFNAR (1) Isotope-Labeled Compounds (5) Ligands for Target Protein for PROTAC (1) Mitophagy (5) MOFs (1) Nucleoside Antimetabolite/Analog (7) p38 MAPK (1) PARP (54) Phosphoramidites (2) Poly(ADP-ribose) Glycohydrolase (PARG) (1) PROTACs (2) PSMA (1) Quinone Reductase (1) Reactive Oxygen Species (ROS) (2) Reference Standards (6) Salt-inducible Kinase (SIK) (1) Topoisomerase (1) Xanthine Oxidase (7)
By Research Areas:	Cancer (55) Cardiovascular Disease (3) Inflammation/Immunology (3) Metabolic Disease (2) Neurological Disease (5)
Oligonucleotides:	Nucleoside Analogs (4) Hypoxanthine (2) Inosine (3) Phosphoramidites (2)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10162

Olaparib Maximum Cited Publications 347 Publications Verification AZD2281; KU0059436	PARP Autophagy Mitophagy	Cancer
Olaparib (AZD2281; KU0059436) is a potent and orally active *PARP* inhibitor with IC₅₀s of 5 and 1 nM for *PARP1* and *PARP2, respectively. Olaparib is an autophagy* and mitophagy activator. Olaparib cannot cross the intact blood-brain barrier (BBB) .

HY-10129

Veliparib 45+ Cited Publications ABT-888	PARP Autophagy	Cancer
Veliparib (ABT-888) is a potent *PARP* inhibitor, inhibiting *PARP1* and *PARP2* with K_is of 5.2 and 2.9 nM, respectively .

HY-132167

Saruparib 15+ Cited Publications AZD5305	PARP	Cancer
Saruparib (AZD5305) is a potent, orally active and selective *PARP* inhibitor and trapper with IC₅₀ values of 3 nM and 1400 nM for PARP1 and PARP2, respectively. Saruparib has anti-proliferative activity and inhibits growth in cells with deficiencies in DNA repair .

HY-100828

BGP-15 3 Publications Verification	PARP	Cardiovascular Disease Cancer
BGP-15 is a *PARP* inhibitor, with an IC₅₀ and a K_i of 120 and 57 μM, respectively.

HY-130250

SR-4835 15+ Cited Publications	CDK Apoptosis	Cancer
SR-4835 is a potent, highly selective and ATP competitive dual inhibitor of CDK12/CDK13 (CDK12: IC₅₀=99 nM, K_d=98 nM; CDK13: K_d=4.9 nM). SR-4835 acts in synergy with DNA-damaging chemotherapy and PARP inhibitors and provokes triple-negative breast cancer (TNBC) cell death .

HY-10162R

Olaparib (Standard) AZD2281 (Standard); KU0059436 (Standard)	Reference Standards PARP Autophagy Mitophagy	Cancer
Olaparib (Standard) is the analytical standard of Olaparib. This product is intended for research and analytical applications. Olaparib (AZD2281; KU0059436) is a potent and orally active *PARP* inhibitor with IC₅₀s of 5 and 1 nM for *PARP1* and *PARP2, respectively. Olaparib is an autophagy* and mitophagy activator .

HY-104044

Pamiparib 3 Publications Verification BGB-290	PARP	Cancer
Pamiparib (BGB-290) is an orally active, potent, highly selective *PARP* inhibitor, with IC₅₀ values of 0.9 nM and 0.5 nM for *PARP1* and *PARP2, respectively. Pamiparib has potent PARP* trapping, and capability to penetrate the brain, and can be used for the research of various cancers including the solid tumor .

HY-137457

Venadaparib 1 Publications Verification IDX-1197	PARP	Cancer
Venadaparib (IDX-1197) is a potent, selective and orally active *PARP* inhibitor with IC₅₀s of 1.4 nM and 1.0 nM for *PARP1* and *PARP2, respectively. Venadaparib does not sensitive to PARP*-5. Venadaparib prevents the repair of DNA single-strand breaks (SSB) and can be used for solid tumors research .

HY-14478

UPF 1069 1 Publications Verification	PARP	Cancer
UPF 1069 is a *PARP* inhibitor, with IC₅₀s of 8 and 0.3 μM for PARP-1 and PARP-2, respectively.

HY-13536

AZD-2461 5+ Cited Publications	PARP	Cancer
AZD-2461 is a potent *PARP* inhibitor, with IC₅₀s of 5 nM, 2 nM and 200 nM for PARP1, PARP2 and PARP3, respectively.

HY-120380

FeTMPyP	MOFs PARP	Neurological Disease
FeTMPyP is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. FeTMPyP inhibits cell death, nitrotyrosine formation, and depolarization of mitochondrial transmembrane potential. FeTMPyP reduces homocysteine-induced nitrosative stress and partially restores TFEB protein and mRNA levels. FeTMPyP improves functional and behavioral deficits caused by chronic constriction injury in rats. FeTMPyP alleviates acute cerebral infarction in a rat model of middle cerebral artery occlusion with mild hyperglycemia. FeTMPyP can be used in studies related to neuropathic pain, renal aging, ischemic penumbra, and hyperglycemic stroke .

HY-W015422

1,5-Isoquinolinediol	PARP	Metabolic Disease
1,5-Isoquinolinediol is a potent *PARP* inhibitor, with an IC₅₀ of 0.18-0.37 μM. 1,5-Isoquinolinediol attenuates diabetes-induced NADPH oxidase-derived oxidative stress in retina .

HY-15044

NU1025	PARP	Neurological Disease Cancer
NU1025 is a potent *PARP* inhibitor with an IC₅₀ of 400 nM and a K_i of 48 nM. NU1025 potentiates the cytotoxicity of ionizing radiation and anticancer agents. NU1025 has anti-cancer and neuroprotective activity .

HY-121497

3-Methoxybenzamide 1 Publications Verification 3-MBA	PARP Bacterial	Cancer
3-Methoxybenzamide (3-MBA), an inhibitor of ADP-ribosyltransferase (ADPRTs) and *PARP*, inhibits cell division in Bacillus subtilis, leading to filamentation and eventually lysis of cells . 3-Methoxybenzamide (3-MBA) enhances in vitro plant growth, microtuberization, and transformation efficiency of blue potato (Solanum tuberosum L. subsp. andigenum) .

HY-Z0283

Benzamide 1 Publications Verification Benzenecarboxamide; Phenylamide	Endogenous Metabolite PARP	Others
Benzamide (Benzenecarboxamide) is a potent poly(ADP-ribose) polymerase (PARP) inhibitor. Benzamide has protective activity against both glutamate- and methamphetamine (METH)-induced neurotoxicity in vitro. Benzamide can attenuate the METH-induced dopamine depletions and exhibits neuroprotective activity in mice, also has no acute effect on striatal dopamine metabolism and does not reduce body temperature .

HY-75706

N-Descyclopropanecarbaldehyde Olaparib	PARP Ligands for Target Protein for PROTAC	Cancer
N-Descyclopropanecarbaldehyde Olaparib is an analogue of Olaparib (HY-10162) containing DOTA moiety. N-Descyclopropanecarbaldehyde Olaparib is a *PARP* inhibitor used for synthesizing novel dual EGFR and PARP PROTAC, DP-C-4 (HY-141481) . N-Descyclopropanecarbaldehyde Olaparib can be radiolabeled with F-18 or fluorophore for positron emission tomography (PET) or optical imaging in several types of tumor .

HY-161430

RTx-161	DNA/RNA Synthesis Apoptosis PARP	Cancer
RTx-161 is a DNA polymerase θ inhibitor with an IC₅₀ of 4.1 nM. RTx-161 induces DNA damage, *PARP* cleavage, apoptosis, and selectively kills homologous recombination-deficient (HRD) cells. RTx-161 acts synergistically with *PARP* inhibitors to suppress *PARP* inhibitor resistance in cancer cells. RTx-161 can be used for the research of BRCA ^G12C mutant cancer and HR-deficient cancers .

HY-15045

INO-1001 2 Publications Verification	PARP	Cancer
INO-1001 is a potent and selective poly (ADP-ribose) polymerase (PARP) inhibitor. INO-1001 is a potent enhancer of radiation sensitivity and enhances radiation-induced cell killing by interfering with DNA repair mechanisms, resulting in necrotic cell death . INO-1001 has anti-tumor effects .

HY-10162S

Olaparib-d5 AZD2281-d₅; KU0059436-d₅	Isotope-Labeled Compounds PARP Autophagy Mitophagy	Cancer
Olaparib-d₅ (AZD2281-d₅) is the deuterium labeled Olaparib (HY-10162). Olaparib is a potent and orally active PARP inhibitor with IC₅₀s of 5 and 1 nM for PARP1 and PARP2, respectively. Olaparib is an autophagy and mitophagy activator .

HY-161302

*Polθ/PARP-IN-1*	Apoptosis DNA/RNA Synthesis PARP	Cancer
Polθ/PARP-IN-1 (compound 25d) is a potent dual DNA polymerase theta (Polθ) and *PARP* inhibitor with IC₅₀ values of 45.6, 5.4 nM, respectively. Polθ/PARP-IN-1 shows antiproliferative activity. Polθ/PARP-IN-1 induces apoptosis and cell cycle arrest at G2/M phase, causes DNA damage. Polθ/PARP-IN-1 shows anti-tumor activity .

HY-133531

PDD00017272	Poly(ADP-ribose) Glycohydrolase (PARG)	Cancer
PDD00017272 is an inhibitor of poly(ADP-ribose) glycohydrolase (PARG) (EC₅₀=4.8 nM) and an activator of *PARP1/2. PDD00017272 inhibits* its activity of hydrolyzing poly(ADP-ribose) (pADPr), resulting in the accumulation of pADPr on chromatin, interfering with DNA damage repair and replication processes, and inducing *PARP1/2*-dependent cytotoxicity. PDD00017272 can be used in cancer models with DNA repair defects (such as BRCA mutations) or resistance to PARP inhibitors. PDD00017272 has a PARG expression level-correlated inhibitory potency with EC₅₀ of 9.2 nM (PARG cells), the tumor cells with lower PARG expression are more sensitive .

HY-G0023

Niraparib metabolite M1 Niraparib carboxylic acid metabolite M1; M1 metabolite of niraparib	Drug Metabolite	Others
Niraparib metabolite M1 is a metabolite of niraparib, and the latter one acts as a novel poly(ADP-Ribose) polymerase (PARP) inhibitor.

HY-160409

TopBP1-IN-1	Topoisomerase Apoptosis	Cancer
TopBP1-IN-1 is a TopBP1 inhibitor. TopBP1-IN-1 has a synergistic effect with *PARP* inhibitors. TopBP1-IN-1 has antitumor activity .

HY-13540

E7016 GPI 21016	PARP	Cancer
E7016 (GPI 21016) is an orally available *PARP* inhibitor. E7016 can enhance tumor cell radiosensitivity in vitro and in vivo through the inhibition of DNA repair. E7016 acts as a potential anticancer agent .

HY-10162S1

Olaparib-d8 AZD2281-d₈; KU0059436-d₈	Isotope-Labeled Compounds PARP Autophagy Mitophagy	Cancer
Olaparib-d₈ (AZD2281-d₈) is the deuterium labeled Olaparib (HY-10162). Olaparib is a potent and orally active PARP inhibitor with IC₅₀s of 5 and 1 nM for PARP1 and PARP2, respectively. Olaparib is an autophagy and mitophagy activator .

HY-144691

PP-C8	PROTACs CDK	Cancer
PP-C8 is a potent and selective PROTAC CDK12-Cyclin K degrader. PP-C8 induces CDK12-Cyclin K degradation with DC₅₀s of 416 and 412 nM for CDK12 and Cyclin K, respectively. PP-C8 demonstrates profound synergistic antiproliferative effects with PARP inhibitor in triple-negative breast cancer (TNBC) .

HY-163743

SIC-19	Salt-inducible Kinase (SIK)	Cancer
SIC-19 is a SIK2 inhibitor and promotes SIK2 protein degradation via the ubiquitination pathway. SIC-19 inhibits cancer cell growth and sensitizes cells to PARP inhibitors (Such as Olaparib (HY-10162)), as well as in ovarian cancer organoids and xenograft models .

HY-161431

RTx-152	DNA/RNA Synthesis	Cancer
RTx-152 traps Polθ on DNA and is an allosteric Polθ-pol inhibitor (IC₅₀: 6.2 nM). RTx-152 selectively kills HR-deficient cancer cells, and suppresses PARP inhibitor resistance in multiple genetic backgrounds, including homologous recombination (HR)-proficient cells. RTx-152 selectively kills BRCA2-null cells .

HY-W141392

2'-Fluoro-5'-O-DMT-2'-deoxyinosine-3'-CE-phosphoramidite	Nucleoside Antimetabolite/Analog Xanthine Oxidase Phosphoramidites	Cancer
2'-Fluoro-5'-O-DMT-2'-deoxyinosine-3'-CE-phosphoramidite is a hypoxanthine analog. Hypoxanthine is a kind of purine base mainly present in muscle tissue. And it is a metabolite produced by purine oxidase acting on xanthine. Hypoxanthine has typical anti-inflammatory effects and is a potential endogenous poly(ADP-ribose) polymerase (PARP) inhibitor. It is cytoprotective by inhibiting PAPR activity, inhibiting peroxynitrite-induced mitochondrial depolarization and secondary superoxide production. Hypoxanthine can also be used as an indicator of hypoxia .

HY-D1107

NCT-TFP	PARP	Others
NCT-TFP is PARP probe used to identifying Poly(ADP-ribose) polymerases (PARP) inhibitors (extracted from patent US20190331688A1) .

HY-155993

YCH1899	PARP	Cancer
YCH1899 is an orally active *PARP* inhibitor, with an IC₅₀< 0.001 nM for PARP1/2. YCH1899 exhibits distinct antiproliferation activity against Olaparib (HY-10162)-resistant and Talazoparib (HY-16106)-resistant Capan-1 cells (Capan-1/OP and Capan-1/TP cells) , with IC₅₀ values of 0.89 and 1.13 nM, respectively. YCH1899 has acceptable pharmacokinetic properties in rats .

HY-15276

4-Aminonaphthalimide	PARP	Cancer
4-Aminonaphthalimide is a potent *PARP* inhibitor and potentiates the cytotoxicity of γ-radiation in cancer cells .

HY-143338

ART-IN-1	PARP	Cancer
ART-IN-1 (compound 7) is a selective *PARP* inhibitor with IC₅₀s of 19, 22, 2.4, >100, 1.1 µM for PARP2, TNKS2, PARP10, PARP14, PARP15, respectively .

HY-105253

PARP-2/1-IN-2	PARP	Neurological Disease
PARP-2/1-IN-2 (Compound 4a), the enantiomer of Veliparib (HY-10129), is a potent *PARP* inhibitor with K_is of 2 and 5 nM against *PARP-2* and *PARP-1, respectively. PARP-2/1-IN-2 has an EC₅₀ of 3 nM in a cell based assay of PARP* activity .

HY-10162S3

Olaparib-d4-1 AZD2281-d₄-1; KU0059436-d₄-1	Isotope-Labeled Compounds PARP Autophagy Mitophagy	Cancer
Olaparib-d₄-1 (AZD2281-d₄-1) is the deuterium labeled Olaparib (HY-10162). Olaparib is a potent and orally active PARP inhibitor with IC₅₀s of 5 and 1 nM for PARP1 and PARP2, respectively. Olaparib is an autophagy and mitophagy activator .

HY-152696

6-O-Methylinosine	Xanthine Oxidase Nucleoside Antimetabolite/Analog	Others
6-O-Methylinosine is a hypoxanthine analogue. Hypoxanthine is a kind of purine base mainly present in muscle tissue. And it is a metabolite produced by purine oxidase acting on xanthine. Hypoxanthine has typical anti-inflammatory effects and is a potential endogenous poly(ADP-ribose) polymerase (PARP) inhibitor. It is cytoprotective by inhibiting PAPR activity, inhibiting peroxynitrite-induced mitochondrial depolarization and secondary superoxide production. Hypoxanthine can also be used as an indicator of hypoxia .

HY-136778

INH2BP	PARP Reactive Oxygen Species (ROS) Bcl-2 Family Caspase ERK p38 MAPK	Cardiovascular Disease
INH2BP is a poly(ADP-ribose) polymerase (PARP) inhibitor with antioxidant and anti-apoptotic activities. INH2BP reduces the production of intracellular reactive oxygen species (ROS), modulates the expression of apoptosis-related proteins such as Bax, Bcl-2 and cleaved caspase-3 and enhances cell survival through the activation of the ERK1/2 and p38 MAPK signaling pathways. INH2BP is promising for research of cardiovascular diseases .

HY-148709

*ARTD10/PARP10-IN-1*	PARP	Inflammation/Immunology
ARTD10/PARP10-IN-1 (compound 23) is a potent and non-selective *PARP* inhibitor, targeting to mono-ADP-ribosyltransferases *ARTD7/PARP15, ARTD8/PARP14, ARTD10/PARP10* and poly(ADP-ribose) polymerase-1 (ARTD1/PARP1) with IC₅₀s of 1.7 μM, 1.6 μM, 0.8 μM, and 4.4 μM, respectively .

HY-121719

TIQ-A	PARP	Cardiovascular Disease Cancer
TIQ-A is a potent TNKS (poly-ART, PARP) inhibitor, with an IC₅₀ of 24 nM for TNKS2. TIQ-A is a potential anti-ischemic agent .

HY-137457A

Venadaparib hydrochloride IDX-1197 hydrochloride	PARP	Cancer
Venadaparib (IDX-1197) hydrochloride is a potent and selective *PARP* inhibitor with anticancer activities. Venadaparib hydrochloride can be used for solid tumors research .

HY-167927

Mefuparib CVL218	PARP	Cancer
Mefuparib (CVL218) is a poly ADP-ribose polymerase (PARP) inhibitor used in cancer research that exhibits potent brain penetration due to its high protein binding.

HY-123232

KU-0058684	PARP	Cancer
KU-0058684 is a potent PARP inhibitor, with an IC₅₀ of 3.2 nM for PARP-1. KU-0058684 significantly reduces DNA double strand break (DSB) repair .

HY-10885

A-620223 succinate ABT-472	PARP	Cancer
A-620223 succinate (ABT-472) is an orally available poly(ADP-ribose) polymerase (PARP) inhibitor. A-620223 succinate (ABT-472) exhibits very good potency against the PARP-1 enzyme with a K_i value of 8 nM and an EC₅₀ value of 3 nM in whole cell assay, making it useful in cancer research .

HY-148710

*ARTD10/PARP10-IN-2*	PARP	Inflammation/Immunology
ARTD10/PARP10-IN-2 (compound 19) is a potent and non-selective *PARP* inhibitor, targeting to mono-ADP-ribosyltransferases *ARTD10/PARP10* and poly(ADP-ribose) polymerase-1 *ARTD1/PARP1* with IC₅₀s of 2.0 μM, and 9.7 μM, respectively .

HY-104044R

Pamiparib (Standard) BGB-290 (Standard)	Reference Standards PARP	Cancer
Pamiparib (Standard) is the analytical standard of Pamiparib. This product is intended for research and analytical applications. Pamiparib (BGB-290) is an orally active, potent, highly selective *PARP* inhibitor, with IC₅₀ values of 0.9 nM and 0.5 nM for *PARP1* and *PARP2, respectively. Pamiparib has potent PARP* trapping, and capability to penetrate the brain, and can be used for the research of various cancers including the solid tumor .

HY-W711852

Benzamide-d5 Benzenecarboxamide-d₅; Phenylamide-d₅	Isotope-Labeled Compounds PARP Endogenous Metabolite	Others
Benzamide-d₅ (Benzenecarboxamide-d₅) is deuterium labeled Benzamide. Benzamide (Benzenecarboxamide) is a potent poly(ADP-ribose) polymerase (PARP) inhibitor. Benzamide has protective activity against both glutamate- and methamphetamine (METH)-induced neurotoxicity in vitro. Benzamide can attenuate the METH-induced dopamine depletions and exhibits neuroprotective activity in mice, also has no acute effect on striatal dopamine metabolism and does not reduce body temperature .

HY-169336

CQ-16	PARP PSMA	Cancer
CQ-16 is an orally active small molecule drug conjugate (SMDC) targeting prostate-specific membrane antigen (PSMA). CQ-16 exhibits highly selective antiproliferative activity between PSMA-positive and PSMA-negative prostate cells. In addition, CQ-16 also has *PARP* inhibitory activity (IC₅₀=1 nM). (Pink: PSMA Ligand (HY-139840); Black: Linker (HY-W037980); Blue: PARP Inhibitor (HY-10162))

HY-W392836

2'-O-Methyl-5'-O-dmt-inosine-3'-CE-phosphoramidite	Nucleoside Antimetabolite/Analog Xanthine Oxidase Phosphoramidites	Cancer
2'-O-Methyl-5'-O-dmt-inosine-3'-CE-phosphoramidite is a hypoxanthine analog. Hypoxanthine is a kind of purine base mainly present in muscle tissue. And it is a metabolite produced by purine oxidase acting on xanthine. Hypoxanthine has typical anti-inflammatory effects and is a potential endogenous poly(ADP-ribose) polymerase (PARP) inhibitor. It is cytoprotective by inhibiting PAPR activity, inhibiting peroxynitrite-induced mitochondrial depolarization and secondary superoxide production. Hypoxanthine can also be used as an indicator of hypoxia .

HY-175466

BER-IN-1	PARP DNA/RNA Synthesis Apoptosis	Cancer
BER-IN-1 is a base excision repair (BER) inhibtor, targeting DNA abasic sites. BER-IN-1 cleaves abasic sites via β- and β,δ-elimination mechanisms, disrupts the base excision repair (BER) pathway and leads to DNA double-strand breaks (DSBs). BER-IN-1 can enhance the effectiveness of the *PARP* inhibitor Olaparib (HY-10162) in homologous recombination (HR)-proficient cancer cells (MDA-MB-231, HeLa, and SKOV3). BER-IN-1 induces an S-phase arrest and apoptosis companied with Olaparib (HY-10162). BER-IN-1 can be used for the research of cancer, such as breast, cervical and ovarian cancer .

HY-162633

USP1-IN-9	Deubiquitinase	Cancer
USP1-IN-9 (Compound 1m) is reversible and noncompetitive ubiquitin-specific proteases (USP1) inhibitors with an IC₅₀ of 8.8 nM, which is designed and synthesized to pyrido[2,3-d]pyrimidin-7(8H)-one derivative based on the disclosed structure of ML323(HY-17543) and KSQ-4279(HY-145471). USP1-IN-9 displays excellent USP1/UAF inhibition and exhibits strong antiproliferation effect in breast cancer cells. USP1-IN-9 can generate enhanced cell killing with PARP inhibitor olaparib(HY-10162) in olaparib-resistant MDA-MB-436/OP cells, which is promising for research in the field of cancer .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-Z0283

Benzamide 1 Publications Verification Benzenecarboxamide; Phenylamide	Alkaloids Human Gut Microbiota Metabolites Classification of Application Fields Other Alkaloids Other Diseases Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite PARP
Benzamide (Benzenecarboxamide) is a potent poly(ADP-ribose) polymerase (PARP) inhibitor. Benzamide has protective activity against both glutamate- and methamphetamine (METH)-induced neurotoxicity in vitro. Benzamide can attenuate the METH-induced dopamine depletions and exhibits neuroprotective activity in mice, also has no acute effect on striatal dopamine metabolism and does not reduce body temperature .

HY-Z0283R

Benzamide (Standard) Benzenecarboxamide (Standard); Phenylamide (Standard)	Structural Classification Alkaloids Human Gut Microbiota Metabolites Other Alkaloids Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite PARP
Benzamide (Standard) is the analytical standard of Benzamide. This product is intended for research and analytical applications. Benzamide (Benzenecarboxamide) is a potent poly(ADP-ribose) polymerase (PARP) inhibitor. Benzamide has protective activity against both glutamate- and methamphetamine (METH)-induced neurotoxicity in vitro. Benzamide can attenuate the METH-induced dopamine depletions and exhibits neuroprotective activity in mice, also has no acute effect on striatal dopamine metabolism and does not reduce body temperature .

Cat. No.	Product Name	Chemical Structure

HY-10162S

Olaparib-d5
Olaparib-d₅ (AZD2281-d₅) is the deuterium labeled Olaparib (HY-10162). Olaparib is a potent and orally active PARP inhibitor with IC₅₀s of 5 and 1 nM for PARP1 and PARP2, respectively. Olaparib is an autophagy and mitophagy activator .

HY-10162S1

Olaparib-d8
Olaparib-d₈ (AZD2281-d₈) is the deuterium labeled Olaparib (HY-10162). Olaparib is a potent and orally active PARP inhibitor with IC₅₀s of 5 and 1 nM for PARP1 and PARP2, respectively. Olaparib is an autophagy and mitophagy activator .

HY-10162S3

Olaparib-d4-1
Olaparib-d₄-1 (AZD2281-d₄-1) is the deuterium labeled Olaparib (HY-10162). Olaparib is a potent and orally active PARP inhibitor with IC₅₀s of 5 and 1 nM for PARP1 and PARP2, respectively. Olaparib is an autophagy and mitophagy activator .

HY-W711852

Benzamide-d5

Benzamide-d₅ (Benzenecarboxamide-d₅) is deuterium labeled Benzamide. Benzamide (Benzenecarboxamide) is a potent poly(ADP-ribose) polymerase (PARP) inhibitor. Benzamide has protective activity against both glutamate- and methamphetamine (METH)-induced neurotoxicity in vitro. Benzamide can attenuate the METH-induced dopamine depletions and exhibits neuroprotective activity in mice, also has no acute effect on striatal dopamine metabolism and does not reduce body temperature .

HY-167927S

Mycophenolic Acid-d3 Acyl-Beta-D-glucuronide
Mycophenolic Acid-d₃ Acyl-Beta-D-glucuronide is the deuterium labeled Mefuparib (HY-167927). Mefuparib (CVL218) is a poly ADP-ribose polymerase (PARP) inhibitor used in cancer research that exhibits potent brain penetration due to its high protein binding.

Cat. No.	Product Name		Classification

HY-W141392

2'-Fluoro-5'-O-DMT-2'-deoxyinosine-3'-CE-phosphoramidite		Phosphoramidites Hypoxanthine
2'-Fluoro-5'-O-DMT-2'-deoxyinosine-3'-CE-phosphoramidite is a hypoxanthine analog. Hypoxanthine is a kind of purine base mainly present in muscle tissue. And it is a metabolite produced by purine oxidase acting on xanthine. Hypoxanthine has typical anti-inflammatory effects and is a potential endogenous poly(ADP-ribose) polymerase (PARP) inhibitor. It is cytoprotective by inhibiting PAPR activity, inhibiting peroxynitrite-induced mitochondrial depolarization and secondary superoxide production. Hypoxanthine can also be used as an indicator of hypoxia .

HY-152696

6-O-Methylinosine		Nucleoside Analogs Inosine
6-O-Methylinosine is a hypoxanthine analogue. Hypoxanthine is a kind of purine base mainly present in muscle tissue. And it is a metabolite produced by purine oxidase acting on xanthine. Hypoxanthine has typical anti-inflammatory effects and is a potential endogenous poly(ADP-ribose) polymerase (PARP) inhibitor. It is cytoprotective by inhibiting PAPR activity, inhibiting peroxynitrite-induced mitochondrial depolarization and secondary superoxide production. Hypoxanthine can also be used as an indicator of hypoxia .

HY-W392836

2'-O-Methyl-5'-O-dmt-inosine-3'-CE-phosphoramidite		Phosphoramidites Hypoxanthine
2'-O-Methyl-5'-O-dmt-inosine-3'-CE-phosphoramidite is a hypoxanthine analog. Hypoxanthine is a kind of purine base mainly present in muscle tissue. And it is a metabolite produced by purine oxidase acting on xanthine. Hypoxanthine has typical anti-inflammatory effects and is a potential endogenous poly(ADP-ribose) polymerase (PARP) inhibitor. It is cytoprotective by inhibiting PAPR activity, inhibiting peroxynitrite-induced mitochondrial depolarization and secondary superoxide production. Hypoxanthine can also be used as an indicator of hypoxia .

HY-154017

2′-C-Methyl-6-O-methylinosine		Nucleoside Analogs Inosine
2′-C-Methyl-6-O-methylinosine is a hypoxanthine analog. Hypoxanthine is a kind of purine base mainly present in muscle tissue. And it is a metabolite produced by purine oxidase acting on xanthine. Hypoxanthine has typical anti-inflammatory effects and is a potential endogenous poly(ADP-ribose) polymerase (PARP) inhibitor. It is cytoprotective by inhibiting PAPR activity, inhibiting peroxynitrite-induced mitochondrial depolarization and secondary superoxide production. Hypoxanthine can also be used as an indicator of hypoxia .

HY-154393

2-Chloro-2'-deoxy-6-O-methylinosine		Nucleoside Analogs Inosine
2-Chloro-2'-deoxy-6-O-methylinosine is a hypoxanthine analog. Hypoxanthine is a kind of purine base mainly present in muscle tissue. And it is a metabolite produced by purine oxidase acting on xanthine. Hypoxanthine has typical anti-inflammatory effects and is a potential endogenous poly(ADP-ribose) polymerase (PARP) inhibitor. It is cytoprotective by inhibiting PAPR activity, inhibiting peroxynitrite-induced mitochondrial depolarization and secondary superoxide production. Hypoxanthine can also be used as an indicator of hypoxia .

HY-152678

6-Methoxypurine-9-β-D-5’(R)-C-methylriboside		Nucleoside Analogs
6-Methoxypurine-9-β-D-5’(R)-C-methylriboside is a hypoxanthine analog. Hypoxanthine is a kind of purine base mainly present in muscle tissue. And it is a metabolite produced by purine oxidase acting on xanthine. Hypoxanthine has typical anti-inflammatory effects and is a potential endogenous poly(ADP-ribose) polymerase (PARP) inhibitor. It is cytoprotective by inhibiting PAPR activity, inhibiting peroxynitrite-induced mitochondrial depolarization and secondary superoxide production. Hypoxanthine can also be used as an indicator of hypoxia .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks